Aardvark Therapeutics, Inc. Common Stock (AARD) Stock
Key stats
- Market cap
- $34.80M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$3.21
- Volume
- Loading
- 52-week high
- $16.60
- 52-week low
- $0.93
Source: third-party data provider, as of November 13, 2026
Compare with AARD
Recent news

All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
AARD

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD

AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
AARD

AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
AARD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.53
- MACD 12/26/9
- -0.84
- EMA 9 of MACD
- -0.92
- MACD histogram
- 0.08
- SMA 50
- $3.94
- Price below SMA 50
- EMA 50
- $3.47
- Price below EMA 50
- SMA 200
- $5.76
- Price below SMA 200
- EMA 200
- $6.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
AARD

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
AARD

AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
AARD

AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
AARD

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
AARD

Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
AARD

Deadline Soon: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Deadline Soon: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
AARD

Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit
Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit
AARD

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action
AARD

Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action
AARD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Tien-Li Lee M.D. | CEO, Secretary & Chairman | 1975 |
| Dr. Bryan Jones Ph.D. | Chief Executive Officer of Ardia | 1964 |
| Mr. Nelson B. Sun M.B.A. | CFO & COO | 1977 |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer | 1981 |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs | — |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer | — |
| Mr. Ron Lewis II, Ph.D. | VP & Head of CMC | — |
| Mr. Justin T. Stege Ph.D. | VP and Head of Project Management & Strategy | — |
| Mr. Derrick C. Li | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.53
- MACD 12/26/9
- -0.84
- EMA 9 of MACD
- -0.92
- MACD histogram
- 0.08
- SMA 50
- $3.94
- Price below SMA 50
- EMA 50
- $3.47
- Price below EMA 50
- SMA 200
- $5.76
- Price below SMA 200
- EMA 200
- $6.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $2.00
- Average
- $6.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +21.3 | -13.8 | -11.0 | -74.2 | +32.5 |



